🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

65,67 USD

Máx. histórico

89,55

119 días

Caída desde máximo

-26,67%

Rango 52 semanas

58,80 – 90,87

Variación hoy

-4,79%

Cierre anterior

68,97

Rango de hoy

65,45 – 69,59

Volumen hoy

1.228.468

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 23 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
28/08/2017 19,36 20,25 19,19 20,11 +4,90% 5,48% 533.500
25/08/2017 19,25 19,51 18,78 19,17 +0,16% 3,79% 371.700
24/08/2017 18,47 19,20 18,11 19,14 +3,91% 5,90% 582.200
23/08/2017 18,84 19,20 18,41 18,42 -3,21% 4,19% 372.500
22/08/2017 17,90 19,04 17,90 19,03 +7,39% 6,37% 447.600
21/08/2017 17,56 18,03 17,17 17,72 +1,26% 4,90% 491.200
18/08/2017 17,46 17,76 16,90 17,50 -0,34% 4,93% 586.900
17/08/2017 17,66 18,07 17,12 17,56 -0,73% 5,38% 454.200
16/08/2017 17,96 18,30 17,53 17,69 -1,83% 4,29% 746.000
15/08/2017 18,81 18,81 17,98 18,02 -3,58% 4,41% 528.700
14/08/2017 19,15 19,28 18,65 18,69 -1,53% 3,29% 553.900
11/08/2017 18,44 19,34 18,02 18,98 +3,43% 7,16% 615.500
10/08/2017 19,41 19,41 17,86 18,35 -5,87% 7,99% 1.130.800
09/08/2017 20,00 20,93 19,36 19,50 +2,07% 7,85% 1.685.500
08/08/2017 19,94 20,25 18,97 19,10 -4,07% 6,42% 515.400
07/08/2017 19,83 20,17 19,68 19,91 +0,81% 2,45% 472.000
04/08/2017 19,18 19,77 18,78 19,75 +4,17% 5,19% 379.400
03/08/2017 18,99 19,42 18,37 18,96 -0,47% 5,53% 617.900
02/08/2017 19,85 20,52 18,86 19,05 -4,56% 8,36% 653.900
01/08/2017 20,79 21,19 19,53 19,96 -3,20% 7,98% 670.900
31/07/2017 20,71 21,09 20,27 20,62 -0,19% 3,96% 284.600
28/07/2017 20,17 20,93 20,16 20,66 +2,43% 3,82% 289.100
27/07/2017 20,89 21,52 20,05 20,17 -3,21% 7,04% 542.200
26/07/2017 21,25 21,54 20,66 20,84 -1,47% 4,14% 319.700
25/07/2017 21,76 21,85 20,79 21,15 -1,86% 4,87% 456.400
24/07/2017 21,48 21,62 20,53 21,55 +0,51% 5,07% 805.400
21/07/2017 20,47 21,65 20,31 21,44 +5,41% 6,55% 817.300
20/07/2017 20,00 20,89 19,80 20,34 +4,68% 5,45% 1.203.000
19/07/2017 19,58 19,84 19,22 19,43 +0,15% 3,17% 450.100
18/07/2017 19,34 19,63 19,06 19,40 +0,15% 2,95% 332.800